A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
Public ClinicalTrials.gov record NCT04014205. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton's Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients With B-Cell Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and Part 2 (dose expansion).
Study identification
- NCT ID
- NCT04014205
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 81 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2019 (Actual)
- Primary completion
- Jun 30, 2026 (Estimated)
- Completion
- Jun 30, 2026 (Estimated)
- Last update posted
- Jun 8, 2026
2019 – 2026
United States locations
- U.S. sites
- 27
- U.S. states
- 18
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic-Mayo Clinic Hospital-Phoenix | Phoenix | Arizona | 85054-4502 | — |
| Pacific Cancer Medical Center | Anaheim | California | 92801-1824 | — |
| Los Angeles Cancer Network - Good Samaritan Hospital Location | Los Angeles | California | 90017 | — |
| Desert Hematology Oncology Medical Group, Inc. | Rancho Mirage | California | 92270 | — |
| The Oncology Institute of Hope & Innovation | Whittier | California | 90603 | — |
| Florida Cancer Specialists (FCS) South | Fort Myers | Florida | 33901 | — |
| Asclepes Research Centers - Weeki Wachee | Weeki Wachee | Florida | 34607 | — |
| Northwest Neurology - Rolling Meadows Office | Elk Grove Village | Illinois | 60007 | — |
| Orchard Healthcare Research Inc. | Skokie | Illinois | 60077 | — |
| Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Cotton O'Neil Cancer Center (Stormont-Vail Cancer Center) | Topeka | Kansas | 66606 | — |
| Tulane University School of Medicine - Tulane Cancer Center Comprehensive Clinic TCCCC | New Orleans | Louisiana | 70112 | — |
| Anne Arundel Medical Center (AAMC) Oncology and Hematology | Annapolis | Maryland | 21401-3093 | — |
| Mayo Clinic - Minnesota | Rochester | Minnesota | 55905-0001 | — |
| Coborn Cancer Center | Saint Cloud | Minnesota | 56303 | — |
| Southeast Nebraska Cancer Center | Lincoln | Nebraska | 68510-2496 | — |
| Summit Medical Group | Florham Park | New Jersey | 07932-0001 | — |
| Clinical Research Alliance | Westbury | New York | 11590 | — |
| Gabrail Cancer Research Center | Canton | Ohio | 44718 | — |
| University of Pittsburgh - Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Guthrie Cancer Center | Sayre | Pennsylvania | 18840 | — |
| Prairie Lakes Cancer Center | Watertown | South Dakota | 57201 | — |
| Tennessee Oncology - Chattanooga Oncology & Hematology Associates | Chattanooga | Tennessee | 37404-1130 | — |
| Tennessee Cancer Specialists | Knoxville | Tennessee | 37909-1327 | — |
| Sarah Cannon Research Institute - Tennessee Oncology | Nashville | Tennessee | 37203-1625 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Medical Oncology Associates PS (dba Summit Cancer Centers) | Spokane | Washington | 99201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04014205, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04014205 live on ClinicalTrials.gov.